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Abstract
Rhomboid proteases, first discovered in Drosophila, are intramembrane serine proteases. Members of the rhomboid protein
family that are catalytically deficient are known as inactive rhomboids (iRhoms). iRhoms have been implicated in wound
healing, cancer, and neurological disorders such as Alzheimer’s and Parkinson’s diseases, inflammation, and skin diseases.
The past decade of mouse research has shed new light on two key protein domains of iRhoms—the cytosolic N-terminal
domain and the transmembrane dormant peptidase domain—suggesting new ways to target multiple intracellular signaling
pathways. This review focuses on recent advances in uncovering the unique functions of iRhom protein domains in normal
growth and development, growth factor signaling, and inflammation, with a perspective on future therapeutic opportunities.

The rhomboid proteins: rhomboid proteases
and rhomboid pseudoproteases
Rhomboid proteins are a highly conserved superfamily of
polytopic membrane proteins (Urban and Dickey 2011).
Rhomboid proteins can be broadly classified into active
(Lastun et al. 2016) and inactive enzymes (Freeman 2014),
also called pseudoproteases or iRhoms. Active rhomboid
proteins, first discovered in Drosophila as key regulators
of epidermal growth factor receptor (EGFR) signaling,
are intramembrane serine proteases that hydrolyze peptide bonds within the lipid bilayer (Lemberg et al. 2005).
Catalysis is achieved by a histidine-serine dyad, which is
submerged 10 Å below the cell membrane surface (Fig. 1A).
Conversely, iRhoms lack a catalytic serine residue and hence
do not retain any enzymatic protease activity (Fig. 1B). Nevertheless, the iRhoms RHBDF1 and RHBDF2 have been
implicated in neurological disorders including Alzheimer’s
and Parkinson’s diseases, as well as in cancer, inflammation, and skin diseases (Jager et al. 2014; Raj et al. 2018;
Hosur et al. 2014; Hosur et al. 2018; Yan et al. 2008; Zhou
et al. 2014; Zou et al. 2009; Blaydon et al. 2012; Young
2019). Nearly a decade of research in mice has emphasized
an essential role for these two proteins in normal functioning

of the brain, heart, skin, eye, bone, adipose tissue, and the
immune system. In line with the role of active rhomboids in
EGFR signaling, findings from mouse models demonstrate
that iRhoms are also essential regulators of EGFR signaling.
While loss-of-function (LOF) mutations in Rhbdf1, Rhbdf2,
or both significantly suppress stimulated secretion of EGFR
ligands, gain-of-function (GOF) mutations in either Rhbdf1
or Rhbdf2 stimulate enhanced EGFR ligand secretion.
iRhoms consist of a long cytosolic N-terminal domain, a
conserved cysteine-rich iRhom homology domain (IRHD),
a six transmembrane (TM helices 1–6) core (Fig. 1B), and an
additional TM segment (TM helix 7). The six TM core harbors the dormant peptidase domain (TM helices 2–6), which
has an alanine residue (instead of serine) in the enzyme core.
In this review, we describe how insights from mouse models carrying either spontaneous mutations or CRISPR/Cas9induced gene modifications in Rhbdf1 and Rhbdf2 have been
crucial in identifying their physiological targets, in defining
the unique roles of iRhom protein domains in development
and disease, and in nominating possible novel therapeutic
opportunities targeting iRhoms.
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mice, suggests that (1) RHBDF1 and RHBDF2 have overlapping functions, as the presence of RHBDF2 reverses
sub-viability and the EOB phenotype in Rhbdf1 KO mice
(Hosur et al. 2020), and (2) RHBDF1 and RHBDF2 share
some physiological functions and targets.

Evidence for distinct targets and function

Fig. 1  Schematic topological models of the Rhomboid proteins. The
rhomboid proteins: both active and inactive rhomboid proteins contain a cytosolic N-terminal domain (N), a six or seven transmembrane
domain (TMD), an extracellular loop or iRhom homology domain
(IRHD) (in the case of iRhoms) in between transmembrane helices
(TMH) 1 and 2, and a C-terminal domain (C). A In the case of active
rhomboids, the catalytic dyad is formed by the highly conserved serine and histidine residues in transmembrane helices 4 and 6, respectively. B iRhoms lack the serine residue in transmembrane helix 4
and hence lack serine protease activity. The E. coli rhomboid protease
GlpG crystal structure shows the catalytic dyad residues serine and
histidine (left) in transmembrane helices 4 and 6. Catalytic serine
has been replaced with alanine in iRhoms in transmembrane helix 4
(right)

Overlapping and discrete functions
of RHBDF1 and RHBDF2 in regulating EGFR
signaling
Evidence for shared targets and function
Homozygous Rhbdf1 knockout mice (KO) exhibit multiorgan pathologies, including brain hemorrhage, cardiac
fibrosis, and lower body weight compared with heterozygous littermates, and die within two weeks after birth
(Christova et al. 2013; Hosur et al. 2020) (Fig. 2A). Conversely, Rhbdf2-null mice are healthy and fertile and do
not present with growth retardation or brain and heart
defects (Hosur et al. 2014; Adrain et al. 2012; McIlwain
et al. 2012; Siggs et al. 2012) (Fig. 2B). Nevertheless, a
combined absence of RHBDF1 and RHBDF2 results in a
more severe phenotype than either Rhbdf1 or Rhbdf2 KO,
as evidenced by sub-viability and eyelids open at birth
(EOB) observed in Rhbdf1:Rhbdf2 double KO mice
(Fig. 2C) (Hosur et al. 2020). This phenotype, together
with the multiorgan pathology exhibited by Rhbdf1-null
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Studies of Rhbdf1 and Rhbdf2 GOF mutant mice (Fig. 2D,
E)—Rhbdf1viable (Hosur et al. 2020), curly bare (Rhbdf2cub),
uncovered (Rhbdf2uncv), and CRISPR/Cas9-mediated genetically engineered mouse model of tylosis with esophageal
cancer (Rhbdf2TOC)—suggest that RHBDF1 and RHBDF2
have distinct functions, and thereby distinct physiological targets. Rhbdf1viable mice, which are generated using
CRISPR/Cas9-mediated excision of exons 2 and 3 of
the Rhbdf1 gene, are healthy, viable, and fertile. Despite
lacking the exons containing the transcription start site
(ATG), the mutant viable transcript produces an N-terminal-truncated RHBDF1 protein (ΔN1–151) using the next
in-frame ATG, which is in exon 4. While most Rhbdf1null mice die by postnatal day 14, no abnormalities are
observed in Rhbdf1viable mice (Fig. 2D), suggesting that
the viable mutation rescues the severe multiorgan pathologies observed in RHBDF1-deficient mice. Additionally,
the viable allele rescues the sub-viability of Rhbdf1:Rhbdf2
double KO mice (Fig. 2F) and induces enhanced stimulated
secretion of EGFR ligands in vitro, suggesting that viable
is a gain-of-function mutation. Consistent with the observations that mutations in the N-terminus of Rhbdf1 result
in GOF mutants, either loss of the N-terminus (loss of
amino acids 1–268 [ΔN1–268], Rhbdf2 cub mutation)
(Hosur et al. 2014; Siggs et al. 2014), or missense mutations (p.P159L, Rhbdf2TOC mutation) (Hosur et al. 2017)
in the N-terminus of Rhbdf2, yields GOF mutant mice.
Each of these two mutations induces, through enhanced
amphiregulin (AREG) secretion, accelerated wound healing and a loss-of-hair phenotype (Fig. 2E). In addition,
uncovered, a recessive mouse mutation (Rhbdf2uncv) results
from a spontaneous loss of 309 bp in the N-terminus
of Rhbdf2 (ΔN118–191) (Li et al. 1999). Like Rhbdf2cub
and Rhbdf2TOC, Rhbdf2uncv mice exhibit a loss-of-hair phenotype. Loss of RHBDF2 does not affect skin architecture or
hair development, indicating that Rhbdf2uncv is a GOF mutation and that mutations in the N-terminus of Rhbdf2 facilitate transmembrane domain (TMD)-mediated enhanced
secretion of EGFR ligands. Interestingly, whereas Rhbdf2
GOF (Rhbdf2cub, Rhbdf2TOC, and Rhbdf2uncv) mutant mice
exhibit a loss-of-hair phenotype through enhanced secretion
of AREG (Christova et al. 2013; Siggs et al. 2012), Rhbdf1
GOF (Rhbdf1viable and Rhbdf1viable2) mutant mice have a normal hair coat (Hosur et al. 2020), suggesting that RHBDF1
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Fig. 2  Loss-of-function
(LOF) and gain-of-function
(GOF) mouse models of
iRhoms. A Rhbdf1-null mice
exhibit brain hemorrhage,
cardiac fibrosis, and lower
body weight than control littermates. B Rhbdf2-null mice
are healthy and fertile and do
not show brain, heart, or growth
defects. C A combined loss
of Rhbdf1 and Rhbdf2 results in
sub-viability and eyelids open at
birth (EOB) phenotype. D GOF
mutations in the Rhbdf1 gene,
such as viable (v) 1, viable
2, and viable 3, produce an
N-terminal-truncated protein
to rescue the overt phenotype
observed in the Rhbdf1-null
mice in panel A. E GOF
mutations in the Rhbdf2 gene,
such as Rhbdf2cub, Rhbdf2uncv,
and Rhbdf2P159L, exhibit a
loss-of-hair phenotype through
enhanced secretion of EGFR
ligand AREG via the TMD. F
The Rhbdf1v/v allele reverses
sub-viability of Rhbdf1:Rhbdf2
double KO mice in panel C.
Rhbdf1v/vRhbdf2−/− mice show
an EOB phenotype and develop
a wavy hair coat; however, no
cardiac or brain abnormalities
are observed in Rhbdf1v/vRhbdf2−/− double mutant mice.
Rectangles indicate deleted
regions
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and RHBDF2 have distinct physiological substrates and nonoverlapping phenotypes.
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Physiological targets of iRhoms

phenotype that is not observed in Rhbdf1-null mice, suggesting that RHBDF2 compensates for the loss of RHBDF1
only during early development to facilitate EGFR signaling,
including during eyelid development, through secretion of
TGFα.

RHBDF1

RHBDF2

In vitro studies in mouse embryonic fibroblasts reveal that
RHBDF1 deficiency suppresses the stimulated secretion
of EGFR ligands, including AREG, heparin-binding EGF
(HB-EGF), and transforming growth factor-alpha (TGFα)
(Hosur et al. 2020; Li et al. 2015). Additionally, short hairpin RNA (shRNA) or small interfering RNA (siRNA)mediated silencing of RHBDF1 in various human breast
cancer cell lines and a human squamous cancer cell line
significantly inhibited TGFα-mediated EGFR signaling and,
further, showed anti-cancer effects by inhibiting cell proliferation and invasion and, ultimately, tumor growth in vivo
(Yan et al. 2008; Zhou et al. 2014; Zou et al. 2009). These
studies suggest that RHBDF1 might regulate EGFR signaling through secretion of multiple EGFR ligands, and that
RHBDF2 does not compensate for the loss of RHBDF1mediated signaling underlying the multiorgan pathologies
observed in Rhbdf1 KO mice.
Despite the clear biological importance of RHBDF1, the
precise molecular mechanisms and the physiological targets
of RHBDF1 underlying the multiorgan pathology and anticancer effects resulting from RHBDF1 deficiency remain to
be investigated. It is unlikely that the pathology observed
in Rhbdf1-null mice is mediated solely through AREG, HBEGF, and/or TGFα, as mice lacking either AREG or TGFα
are healthy and fertile (Luetteke et al. 1999; Luetteke et al.
1993; Mann et al. 1993). However, RHBDF1 likely regulates
the secretion of more than one EGFR ligand. In particular,
the cardiac fibrosis observed in Rhbdf1-null mice resembles the heart enlargement displayed by Hbegf-null mice
(Iwamoto et al. 2003), and the eyelids open at birth (EOB)
observed in Rhbdf1:Rhbdf2 double KO mice resembles the
EOB phenotype displayed by Hbegf and Tgfa double null
mice (Mine et al. 2005). Together, these observations suggest that HB-EGF and TGFα could be the physiological targets of RHBDF1.
If defects in EGFR signaling alone underlie the multiorgan pathology observed in Rhbdf1-null mice, it is likely that
RHBDF2 compensates for the loss of RHDBF1 during early
development through secretion of TGFα, particularly during
eyelid development. This is because, although Rhbdf1-null
mice exhibit multiorgan pathology (Hosur et al. 2020), they
do not exhibit the in utero lethality, EOB phenotype, and epidermal defects observed in Egfr-null mice (Miettinen et al.
1999; Sibilia and Wagner 1995). Furthermore, mice lacking both HB-EGF and TGFα show a highly penetrant EOB

In vitro, loss of RHBDF2 has been shown to result in significantly reduced stimulated secretion of EGFR ligands,
including AREG, HB-EGF, and TGFα (Siggs et al. 2014;
Maretzky et al. 2013). In vivo studies in mice suggest that
AREG is a bona fide physiological target of RHBDF2. In
humans, dominant mutations in RHBDF2 cause tylosis with
esophageal cancer (TOC) syndrome through a hyperactive
EGFR signaling pathway. Using spontaneous (Rhbdf2cub/cub
and Rhbdf2cub/cub Areg−/−) (Hosur et al. 2014) and CRISPR/
Cas9 (Rhbdf2TOC) (Hosur et al. 2017) genetically engineered
mouse models, we have shown that dominant mutations in
RHBDF2 induce a hyperactive EGFR phenotype through
enhanced secretion of AREG, and that genetic deletion
of Areg in Rhbdf2cub/cub mice or Rhbdf2TOC mice prevents
TOC. Further, shRNA-mediated silencing of Areg inhibits
the hyperactive EGFR signaling phenotype in Rhbdf2cub/cub
embryonic fibroblasts (Hosur et al. 2014). Together, these
studies suggest that AREG is a physiological target of
RHBDF2.
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Cytosolic N‑terminus and TM helix 1
of RHBDF1 are dispensable for normal
growth and development
The Rhbdf1viable mutation generates an N-terminal-truncated
RHBDF1 protein (ΔN1–151) (Fig. 3A, B), which rescues
the severe multiorgan pathologies observed in RHBDF1deficient mice (Fig. 2D). Notably, even in the absence of the
N-terminal domain, the mutant Rhbdf1v/v transcript generated by the Rhbdf1v/v mutation induces enhanced secretion
of EGFR ligands, suggesting that the IRHD and the TMD of
RHBDF1 are sufficient to mediate EGFR signaling.
Rhbdf1viable2 mice, which were first generated by Li X.
et al. are Rhbdf1 homozygous mutant mice lacking exons
4–11 in the Rhbdf1 gene (Li et al. 2015). The resulting Rhbdf1 mutant transcripts yield two variant proteins
(~ 32 and ~ 29 kDa) that each lack the entire N-terminus,
the TM helix 1, and the majority of the IRHD (Fig. 3C).
Like Rhbdf1viable mice, Rhbdf1viable2 mice are healthy and
fertile and do not exhibit the cardiac, brain, or growth defects
observed in Rhbdf1-null mice. Rhbdf1viable2 mice are referred
to by this name because of the phenotypic similarity to
Rhbdf1viable mice. Since the N-terminus, the TM helix 1,
and the majority of the IRHD are lost in Rhbdf1viable2 mice,
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Fig. 3  Domains of RHBDF1
gain-of-function proteins. A A
schematic of the full-length
mouse RHBDF1 protein showing the cytosolic N-terminus
domain, IRHD, transmembrane
helices, and the peptidase
domain. B A schematic of the
mouse RHBDF1 viable protein showing the loss of 151
amino acids in the N-terminal
domain. C A schematic of the
mouse RHBDF1 viable2 protein showing the complete loss
of the cytosolic N-terminal
domain and the partial loss of
the IRHD (Targeted KO-first
allele). D A schematic of the
mouse RHBDF1 viable3 protein showing the complete loss
of the N-terminal domain and
the partial loss of the IRHD.
Notably, all three mutant
proteins, viable, viable2,
and viable3 retain the dormant
peptidase domain (CRISPR/
Cas9 generated allele)

and these mice remain healthy and fertile, we reasoned that
the entire N-terminus, the IRHD, and the TM helix 1 might
be dispensable. Instead, we found that either of the two variant proteins, each consisting solely of TM helices 2–7, is
adequate to rescue the Rhbdf1-null phenotype (Hosur et al.
2020). This result explains the healthy and fertile phenotypes observed in Rhbdf1viable and Rhbdf1viable2 mice, with
no brain, heart, or body weight defects.
The Rhbdf1viable2 homozygous mutant mice reported by
Li et al. were generated using the KO-first gene disruption
strategy. Nevertheless, the Rhbdf1viable2 mutant mice are
not homozygous-null because the Rhbdf1viable2 mutant transcript generates truncated proteins through an alternative
promoter usage and through exon skipping. Interestingly,
DNA sequencing revealed that the Rhbdf1viable2 allele retains
the En2 splice acceptor sequence from the cassette used to
generate the KO-first allele, resulting in novel mutant transcripts lacking the N-terminus, TM helix 1, and the majority
of the IRHD (72%) (Hosur et al. 2020). Thus, to further validate if the N-terminus, TM helix 1, and the majority of the
IRHD are dispensable, we generated Rhbdf1viable3 mice using
CRISPR/Cas9-mediated gene editing in C57BL/6 J mice.
We excised exons 4 through 13 in the Rhbdf1 gene, resulting

in mice lacking the N-terminus, the first TM helix 1, and
72% of the IRHD, but that retain TM helices 2–7 that harbor
the dormant peptidase domain (Fig. 3D). We refer to these
mice as viable 3 (Rhbdf1v3) (unpublished observations). We
observed that homozygous-viable 3 (Rhbdf1v3/v3) mice did
not display any gross deformities of major organs, which is
consistent with both the Rhbdf1viable (Rhbdf1ΔN1-151) mice
and Rhbdf1viable2 (lacking exons 4–11) mice, and in contrast
to the Rhbdf1null/null mice that show multiorgan pathology
and die within two to three weeks. Collectively, these studies suggest that the cytosolic N-terminus, TM helix 1, and
possibly the IRHD of RHBDF1 are dispensable for normal
growth and development.

Cytosolic N‑terminus and TM helix 1
of RHBDF2 regulate inflammatory signaling
through TNFα secretion
While the N-terminus and the TM helix 1 of iRhoms are
dispensable for normal growth and development, they nevertheless play an important role in RHBDF2-mediated inflammatory signaling. In mice, loss of RHBDF2 significantly
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reduces regulated secretion of TNFα following stimulation
with bacterial endotoxin lipopolysaccharide (LPS) (Hosur
et al. 2014; Adrain et al. 2012; McIlwain et al. 2012; Siggs
et al. 2012). Particularly, the N-terminus seems to be essential for TNFα secretion, because Rhbdf2cub mice, which lack
the N-terminal domain similarly to Rhbdf2-null mice, show
significantly reduced TNFα secretion upon stimulation with
LPS, demonstrating that the N-terminal domain is essential for TNFα secretion (Hosur et al. 2014). Concordantly,
Cavadas et al. and Grieve et al. found that phosphorylation of RHBDF2 at the N-terminus is essential for TNFα
secretion (Cavadas et al. 2017; Grieve, et al. 2017); upon
stimulation with LPS, RHBDF2 serine phosphorylation and
binding to 14–3–3 proteins was observed in primary macrophages. Additionally, in Rhbdf2 KO macrophages, LPSinduced TNFα secretion was rescued by RHBDF2, but not

by N-terminal-truncated RHBDF2 lacking phosphorylation
sites (58–361 aa) (Fig. 4A), suggesting that RHBDF2 phosphorylation and binding to 14–3–3 proteins controls TNFα
release in macrophages. In addition to binding of 14–3–3
proteins, FRMD8 has been shown to be a binding partner for
RHBDF2. Künzel et al. and Oikonomidi et al. suggest that
the N-terminus of RHBDF2 forms a tripartite complex with
FRMD8 and ADAM17, a metalloprotease essential for ectodomain shedding of TNFα, to facilitate inflammatory signaling through stimulated secretion of TNFα (Künzel et al.
2018; Oikonomidi et al. 2018). The authors showed that
stimulation of Frmd8 KO macrophages with LPS resulted
in reduced secretion of TNFα, suggesting that FRMD8RHBDF2 interaction is necessary for TNFα secretion.
It has been suggested that the TM helix 1 of RHBDF2
is also essential for TNFα secretion in macrophages (Li

Fig. 4  RHBDF2 binding partners and iRhoms macrophage
expression. A A schematic of the full-length mouse RHBDF2
protein showing the 14–3-3 and FERM Domain Containing 8
(FRMD8) binding sites in the cytosolic N-terminal domain and
the sinecure mutation I387F in transmembrane helix 1. B Vio-

lin plots showing expression of various mouse and human genes
in macrophages. In both mouse (left panel) and human (right
panel) macrophages, Rhbdf1, Rhbdf2, Tnfa, and Adam17 are
expressed. Cd19 and Cd3g serve as negative markers,
whereas Cd14 and Fcgr1 serve as positive controls, in macrophages
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et al. 2017). Like Rhbdf2-null mice, mice homozygous for
the sinecure (sin) mutation, a recessive mutation in the
Rhbdf2 gene, are viable and fertile (Siggs et al. 2012). The
Beutler laboratory identified sinecure during a forward
genetic screen of mice for regulators of Toll-like receptor (TLR)-induced TNFα secretion. A single nonsynonymous mutation (A to T) in Rhbdf2 results in conversion
of isoleucine to phenylalanine at amino acid 387 (I387F)
(Fig. 4A). Non-complementation studies validated
that sinecure is a mutation at the Rhbdf2 locus, as compound mutant Rhbdf2sin/null mice and Rhbdf2sin/sin Rhbdf2null mice showed similar reductions in TNFα secretion
following stimulation with LPS. TNFα secretion was not
completely blocked, suggesting that constitutive secretion
of TNFα is not affected by RHBDF2 deficiency. These
data suggest that TM helix 1 of RHBDF2 is essential for
stimulated secretion of TNFα.
Interestingly, the binding partners for the N-terminus
of RHBDF2—14–3–3 proteins and FRMD8—seem to be
dispensable for RHBDF1-mediated growth factor signaling. We recently generated Ywhaq (14–3–3 theta) KO
mice and observed that, compared with heterozygousnull mice (Ywhaq±), homozygous-null mice (Ywhaq−/−)
showed reduced TNFα secretion following stimulation
with LPS. However, Ywhaq-null mice exhibit normal
body weight, no postnatal lethality, nor any brain or heart
defects, as observed in Rhbdf1 KO mice. This suggests
that YWHAQ could be a binding partner for RHBDF2
and that it might be essential for RHBDF2-mediated
stimulated secretion of TNFα, but not for RHBDF1mediated growth factor signaling (unpublished observations). In line with these findings, FRMD8 also seems
to be essential for TNFα secretion, but not for growth
factor signaling. Specifically, we generated Frmd8 KO
mice and observed that, compared with heterozygousnull mice (Frmd8 ±), homozygous-null mice (Frmd8 −/−)
showed significantly reduced TNFα secretion following
stimulation with LPS, in accordance with the observations of Künzel et al. and Oikonomidi et al. However,
Frmd8 KO mice do not phenocopy Rhbdf1 KO mice in
terms of lower body weight, postnatal lethality, or brain
and heart defects (unpublished observations). This suggests that FRMD8 could also be a binding partner for
RHBDF2 and might be essential for RHBDF2-mediated
stimulated secretion of TNFα, but not for RHBDF1. More
importantly, RHBDF2-mediated stimulated secretion of
TNFα suggests high specificity of RHBDF2 for TNFα.
Even though RHBDF1 is expressed in both mouse and
human macrophages (Fig. 4B), it does not compensate
for the loss of RHBDF2 in regulating stimulated secretion of TNFα, suggesting that TNFα could be a specific
target of RHBDF2.
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The dormant peptidase domain of iRhoms
(TM helices 2–6)
Peptidase domain of RHBDF1 is sufficient for normal
growth and development. In an in vivo screen in mice, we
identified the minimal protein domain required for normal
growth and development—the transmembrane peptidase
domain of RHBDF1. The healthy and fertile phenotypes
of Rhbdf1viable (ΔN1–151), Rhbdf1viable2, Rhbdf1viable3, and
Rhbdf1viable Rhbdf2−/− mice (Hosur et al. 2020) (Fig. 2D,
F), with no defects in the brain, heart, or in body weight,
surprisingly suggest that RHBDF2 and the N-terminus, the
IRHD, and the first TM helix of RHBDF1 are dispensable
for normal growth and development (Hosur et al. 2020).
However, TM helices 2–6, which harbor the dormant
peptidase domain of RHBDF1, are adequate and essential
for survival and normal growth and development.
Peptidase domain of RHBDF2 facilitates AREG secretion. The Rhbdf2cub spontaneous mouse mutation results
from a ~ 12.5 Kb deletion in the Rhbdf2 gene, leading to
the loss of exons 2 through 6. Nevertheless, the Rhbdf2cub mutant transcript generates an N-terminal-truncated
protein using an in-frame ATG in exon 8 resulting in lossof-hair and rapid wound healing phenotypes. We previously showed that the N-terminal-truncated transcript is
sufficient to induce AREG secretion, leading to a hyperactive EGFR phenotype. Furthermore, using site-directed
mutagenesis, we showed that mutating residues in TM
helices 2, 4, and 6, which harbor the dormant peptidase
domain, prevents AREG secretion, suggesting that the dormant peptidase domain of RHBDF2 is sufficient to facilitate AREG secretion, and that the N-terminal domain is
dispensable for mediating the hyperactive EGFR phenotype observed in Rhbdf2cub mice (Hosur et al. 2014).

Highly conserved amino acid residues
in the dormant peptidase domain of iRhoms
As noted above, the dormant peptidase domain of
RHBDF2 is sufficient to induce accelerated wound healing in mice through enhanced secretion of AREG (Hosur
et al. 2014). Furthermore, the survival of Rhbdf1 viable2
and Rhbdf1 viable3 mice indicates that the dormant peptidase domain is sufficient for survival. Nevertheless, the
underlying molecular mechanisms are unclear. Here, we
perform new sequence analysis of key amino acid residues in the peptidase domain of the rhomboid family using
HMM Logos, a widely used tool for visualization of protein families, and uncover highly conserved amino acid
residues in TM helices 2, 3, 4 and 6. We thus propose
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that these amino acids could be critical for RHBDF1- and
RHBDF2-mediated EGFR signaling (Fig. 5A). We further propose that the dormant peptidase domain could also
account for differences in substrate specificity of RHBDF1
and RHBDF2. For instance, even though both Rhbdf1 and
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Rhbdf2 are expressed in keratinocytes (Fig. 5B), RHBDF2,
but not RHBDF1, selectively induces accelerated wound
healing in mice through enhanced AREG secretion. Therefore, RHBDF1 and RHBDF2 have high specificity toward
target proteins, which might be conferred by the peptidase

Inactive rhomboid proteins RHBDF1 and RHBDF2 (iRhoms): a decade of research in murine models	
◂Fig. 5  Sequence

alignment
of
the
rhomboid
peptidase
domain. A Sequence alignment of the peptidase domain of the
rhomboid family of proteins showing highly conserved catalytic
serine and histidine residues in transmembrane helix (TMH) 4 and
TMH6, respectively. Rhomboid proteins lacking the catalytic dyad
(serine and/or histidine residues) do not show protease activity
(highlighted residues). B Violin plots showing expression of various mouse and human genes in keratinocytes. In both mouse (left
panel) and human (right panel) keratinocytes, Rhbdf1, Rhbdf2, Areg,
Tgfa, and Adam17 are expressed. C Sequence alignment of mouse
and human rhomboid dormant peptidase domain with non-similar
residues between RHBDF1 and RHBDF2 highlighted. D Amino acid
residues in TMH 5 and 6 that are non-similar between RHBDF1 and
RHBDF2 in both human and mouse (left panel). The crystal structure
of the E. coli rhomboid protease GlpG was used to indicate the nonsimilar residues in TMH 5 and 6 (right)

domain. In addition, RHBDF2 shows high specificity for
TNFα (Hosur et al. 2014; Adrain et al. 2012; McIlwain
et al. 2012; Siggs et al. 2012). Despite significant sequence
homology, there are several amino acids, particularly in
TM helices 5 and 6, that are dissimilar in both humans and
mice between RHBDF1 and RHBDF2 (Fig. 5C). Previously, it has been suggested that amino acid residues in the
transmembrane domain of the substrate (e.g., TGFα, EGF)
determine specificity of rhomboid proteases (Urban and
Freeman 2003); however, it is likely that amino acid residues in TM helices 5 and 6 of the peptidase domain could
also account for differences in specificity. Because TM
helix 5, which tilts its top ~ 35° laterally from the enzyme
core (Fig. 5D), acts as the substrate gate (Baker et al.
2007), differences in amino acid residues in TM helix 5
could govern substrate specificity. However, future studies
are needed to more thoroughly define the role of the dormant peptidase domain in conferring specificity for targets.

How do iRhoms regulate secretion of EGFR
ligands and TNFα?
The underlying mechanisms are still emerging, but two
hypotheses have been proposed based on available data:

ADAM17 hypothesis
iRhoms have been shown to regulate maturation, trafficking,
and activation of ADAM17, a metalloprotease required for
ectodomain shedding of EGFR ligands and TNFα (Adrain
et al. 2012; McIlwain et al. 2012; Maretzky et al. 2013).
Thus, according to this hypothesis, mice lacking Rhbdf1 or
Rhbdf2 or both together fail to promote ADAM17 activity,
thereby leading to significantly reduced secretion of EGFR
ligands and TNFα following stimulation with phorbol ester
or LPS. However, genetic evidence deduced from the mouse
models that we and others have generated argue against this
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hypothesis. First, the necessity of RHBDF2 for ADAM17
maturation and trafficking raises an obvious question as to
why Rhbdf2 KO mice do not phenocopy Adam17 KO mice.
Notably, whereas Adam17 KO results in embryonic or perinatal lethality (Veit 2019), Rhbdf2 KO mice are viable and
fertile. To this end, Issuree et al. (Issuree et al. 2013) suggested that RHBDF1 compensates for the loss of RHBDF2
in Rhbdf2 KO mice and facilitates ADAM17 maturation and
trafficking, and hence Rhbdf2 KO mice do not phenocopy
Adam17 KO mice. Consistent with the Issuree et al. study,
Li et al. (2015) showed that, whereas Rhbdf1 and Rhbdf2
single KO mice are viable and fertile, Rhbdf1/Rhbdf2 double
KO mice phenocopy Adam17 KO mice, exhibiting perinatal
lethality, open eyelids at birth, and heart valve defects. Li
et al.’s findings are in direct conflict with the results of a
previous study by Christova et al. (2013), who found that
Rhbdf1 single KO mice have multiorgan pathologies, and
Rhbdf1:Rhbdf2 double KO mice show early embryonic
lethality. To try to resolve this discrepancy, we found that
both the Rhbdf1 single KO mice and the Rhbdf1/Rhbdf2 double KO mice generated by Li et al. are indeed not null for
RHBDF1 as they retain residual RHBDF1 functional activity
(Hosur et al. 2020). This brings into question the notion as
to whether RHBDF1 compensates for the loss of RHBDF2
in regulating ADAM17 maturation and trafficking, and the
association in general between iRhoms and ADAM17 maturation, trafficking, and activation. Second, transcriptome data
suggest that macrophages (human and mouse) express both
Rhbdf1 and Rhbdf2 (Fig. 4B). According to the ADAM17
hypothesis, loss of RHBDF2 is compensated by RHBDF1,
and vice versa. However, Rhbdf2 KO macrophages show significantly reduced stimulated secretion of TNFα (Hosur et al.
2014; Adrain et al. 2012; McIlwain et al. 2012; Siggs et al.
2012), even though Rhbdf1 is expressed in Rhbdf2-null macrophages, arguing against the iRhoms-ADAM17 hypothesis.
Third, Rhbdf2-null mice show reduced stimulated secretion
of EGFR ligands, including AREG and TGFα, in keratinocytes. It has been suggested that loss of RHBDF2 fails to
promote ADAM17 maturation, trafficking, and activity, leading to the reduction in stimulated secretion of EGFR ligands.
Again, according to the ADAM17 hypothesis, RHBDF1,
which is abundantly expressed in keratinocytes (Fig. 5B),
compensates for the loss of RHBDF2. However, contrary to
this prediction, Rhbdf2-null keratinocytes show significantly
reduced stimulated secretion of EGFR ligands. Lastly, and
more importantly, this hypothesis does not account for target
specificity of RHBDF1 and RHBDF2. For instance, GOF
mutation in Rhbdf2 (Rhbdf2cub), but not in Rhbdf1 (Rhbdf1viable), selectively regulates AREG secretion to induce lossof-hair and wound healing phenotypes. Therefore, it seems
unlikely that iRhoms regulate secretion of EGFR ligands and
TNFα through direct regulation of ADAM17 maturation,
trafficking, and activation.
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Target trafficking hypothesis
According to this hypothesis, RHBDF1 regulates secretion
of EGFR ligand TGFα through delivery of pro-TGFα to the
plasma membrane, where pro-TGFα undergoes ectodomain
shedding by ADAM17 to release TGFα. In breast cancer
cell lines, Li J. et al. showed that RHBDF1 is an essential
component of the protein trafficking machinery involving
clathrin-coated vesicles (Li et al. 2018). Following stimulation with the G-protein-coupled receptor agonist Sphingosine 1 Phosphate (S1P), RHBDF1 participates in clathrin
uncoating of vesicles to deliver pro-TGFα to the cell surface.
Specifically, RHBDF1 interacts with a clathrin-coated vesicle protein auxilin-2 to recruit Heat shock cognate protein
(HSC70) to the vesicles to initiate clathrin uncoating. Furthermore, siRNA-mediated silencing of RHBDF1 inhibits
the interaction between HSC70 and auxilin-2, significantly
reducing TGFα secretion by preventing uncoating of clathrin
and delivery of pro-TGFα to the plasma membrane for ectodomain shedding. Although in vivo validation is required
to further support the target trafficking hypothesis, these
findings could help address certain unanswered questions,
such as the observation that Rhbdf2 KO macrophages demonstrate reduced stimulated secretion of TNFα. According
to the target trafficking hypothesis, RHBDF2 deficiency
does not affect ADAM17 activity, but due to target specificity (RHBDF2 for TNFα), RHBDF2 deficiency in macrophages, regardless of RHBDF1 expression, suppresses
TNFα secretion.

L. M. Burzenski et al.

inflammation, and skin diseases suggests iRhoms as potential therapeutic targets. Particularly, since ADAM17 inhibition to block secretion of EGFR ligands, including AREG,
is associated with severe adverse effects (Ieguchi and Maru
2016), identification of selective inhibitors of the dormant
peptidase domain—although challenging—could lay the
foundation for the development of more selective and effective therapeutics targeting iRhoms to abrogate multiple
pathogenic signaling pathways.

Highlights
• Rhomboid proteases, first discovered in Drosophila, are

•

•

•

Concluding remarks
iRhoms are characterized by a cytosolic N-terminal domain,
a luminal IRHD, and a transmembrane dormant peptidase
domain. Since the initial discovery in Rhbdf2cub mice that in
the absence of the cytosolic N-terminal domain, the dormant
transmembrane peptidase domain of RHBDF2 is sufficient
to regulate EGFR signaling through secretion of EGFR
ligand AREG, a substantial amount of literature has revealed
the biological functions of iRhoms domains. Furthermore,
the normal development and survival of Rhbdf1viable3 mice
demonstrates that whereas the N-terminal domain and the
IRHD are dispensable for viability and fecundity, the loss of
the transmembrane dormant peptidase domain is associated
with developmental defects, indicating that the peptidase
domain is essential and is sufficient to regulate the secretion of diverse EGFR ligands. Although in vitro biochemical
assays indicate some redundant functions for RHBDF1 and
RHBDF2 in controlling secretion of various EGFR ligands,
mouse genetic studies reveal unique signaling pathways and
distinct client proteins for iRhoms. Additionally, uncovering the pathological role of iRhoms in epithelial cancers,
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•
•

intramembrane serine proteases. Members of the rhomboid protein family lacking protease activity are known
as inactive rhomboids (iRhoms) or pseudoproteases.
Both spontaneous and genetically engineered mouse
models of iRhoms have been critical tools to explore the
molecular and cellular functions of key iRhom protein
domains—the cytosolic N-terminus, and the transmembrane dormant peptidase domain—in development and
disease.
The N-terminus and the dormant peptidase domain have
opposing roles. While the N-terminus negatively regulates EGFR signaling, the dormant peptidase domain
stimulates EGFR signaling when not suppressed by the
N-terminus.
RHBDF1 and RHBDF2 have both discrete and overlapping functions during development. For survival and normal growth, the dormant peptidase domain of RHBDF1
is adequate to compensate for the loss of the N-termini
of iRhoms and for the complete loss of RHBDF2.
The N-terminal domain and TM helix 1 of RHBDF2 are
essential for TNFα secretion.
The iRhom homology domain (IRHD) of RHBDF1
appears to be dispensable for survival and/or ligand
secretion, but the role of the IRHD of RHBDF2 is
unknown.

Outstanding questions
• Rhbdf1 KO mice die of brain hemorrhage and car-

diac fibrosis. What are the physiological substrates of
RHBDF1 and the underlying signaling pathways that
maintain brain and heart function? Addressing these
questions may have implications for treating neurological disorders, such as Alzheimer’s and Parkinson’s, as
well as cardiac abnormalities.
• TM helices 2–6, which harbor the dormant peptidase
domain, of iRhoms are essential for stimulated secretion
of EGFR ligands. Which amino acid residues in the dor-
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mant peptidase domain regulate secretion in vivo? These
findings will help in rational drug design of potential
novel treatments for cancer and skin diseases.
• iRhoms have overlapping functions only during developmental stages. Why does RHBDF2 not rescue multiorgan pathology, including brain hemorrhage and cardiac
fibrosis, in Rhbdf1-null mice? Is RHBDF2 not expressed
in the brain and heart during later stages, i.e., postnatal
days?
• There is a need to understand tissue-specific regulation
of EGFR ligand secretion by iRhoms. Mutations in the
N-terminus (Rhbdf2TOC) or loss of the entire N-terminus
(Rhbdf2cub) in RHBDF2 enhance AREG secretion to
cause a hair loss phenotype. However, mutations in the
N-terminus (Rhbdf1viable) or loss of the entire N-terminus
(Rhbdf1viable3) in RHBDF1 do not result in a similar phenotype.
Note Tissue-specific gene expression data were obtained
from the ARCHS4 database, which provides access to gene
counts from HiSeq 2000, HiSeq 2500, and NextSeq 500
platforms for human and mouse experiments from GEO
and SRA (Lachmann et al. 2018). We downloaded expression files (gene-level) for mouse (mouse_matrix_v10.h5)
and human ((human_matrix_v10.h5) and selected the samples with tissue annotation from metadata as macrophages
(Fig. 4A) and keratinocytes (Fig. 5B).
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